Physician profile
Candyce Miller
NPI 1245270883
$3,430.14
in general payments reported to CMS, 2019-2025
27 companies · $539 in 2025
The $539 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $900 · 2022: $740 · 2023: $629 · 2024: $622 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $975.26 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $509.77 | 2021-2024 | |
| Lilly USA, LLC | $244.88 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Mannkind Corporation | $232.32 | 2021-2023 | Afrezza |
| Pfizer INC. | $196.25 | 2021-2025 | |
| Amgen INC. | $183.98 | 2021-2023 | Repatha |
| Xeris Pharmaceuticals, INC. | $181.77 | 2021-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $127.47 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $86.56 | 2021-2023 | Farxiga |
| Exact Sciences Corporation | $84.99 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $72.54 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $64.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.42 | 2021-2023 | Jardiance |
| Zealand Pharma US, INC. | $48.24 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.60 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rgh Enterprises LLC | $42.00 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $41.08 | 2021 | |
| Hologic Sales and Service, LLC | $37.05 | 2025 | Aptima |
| Inspire Medical Systems, INC. | $33.36 | 2024 | Inspire |
| Bausch Health US, LLC | $23.80 | 2022 | |
| Globus Medical, INC. | $23.29 | 2025 | Senza |
| Novartis Pharmaceuticals Corporation | $23.21 | 2021 | |
| Esperion Therapeutics, INC. | $20.64 | 2021 | |
| Sanofi Pasteur INC. | $18.24 | 2025 | |
| Insulet Corporation | $17.73 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.83 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.33 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candyce Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.